Trust Signals
Key Takeaways
- CJC-1295 with DAC has the strongest human pharmacokinetic data of any GHRH analog in this category, with a published half-life of roughly 6 to 8 days and documented IGF-1 increases in a phase II trial (Teichman et al., 2006).
- IGF-1 LR3 has a half-life approximately 60 to 120 times longer than native IGF-1, giving it sustained mTOR-pathway activation, but hypoglycemia is a documented dose-dependent risk even at research doses.
- Ipamorelin is the most ghrelin-receptor-selective GHRP tested, producing GH pulses with less cortisol and prolactin co-secretion than GHRP-2 or GHRP-6, based on rodent and limited human pharmacology data.
- BPC-157 has zero published human RCTs for muscle gain or injury recovery. Its inclusion in bulking stacks is based on rodent wound-healing studies only.
- All GH secretagogues, IGF-1 analogs, and related peptides are prohibited in competition under WADA S2. Legal status for human use in the US is a gray area; none are FDA-approved for muscle gain in healthy adults.
What Are the Best Peptides for Bulking?
The best peptides for bulking, ranked by evidence quality and anabolic mechanism strength, are IGF-1 LR3, CJC-1295 with DAC, ipamorelin, GHRP-2, and BPC-157 as a recovery adjunct. Each targets a different node in the GH/IGF-1 axis. None match the lean-mass effect size of approved anabolics in direct comparisons, but several carry a more favorable androgenic side-effect profile.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: How Strong Is the Data?
- Mechanism with Numbers: How These Peptides Build Muscle
- The Ranked List: 5 Best Peptides for Bulking
- What Most Pages Get Wrong About Bulking Peptides
- The Chemistry Behind Storage and Stability Rules
- Honest Head-to-Head: Peptides vs Real Alternatives
- Dosing and Protocol Table
- Label and COA Literacy: How to Evaluate a Product
- FAQ
- Sources
- Disclaimers
Evidence Ledger: How Strong Is the Data?
Every major claim about bulking peptides should be graded. Here is the honest picture.
| Peptide / Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| CJC-1295 raises IGF-1 in humans | Human phase II dose-escalation trial (Teichman et al., 2006, n=65) | Positive, dose-dependent | Moderate-High |
| CJC-1295 produces lean mass gain | Human trial (Teichman et al., 2006 noted body composition trending; not primary endpoint) | Trend positive, not confirmed | Low |
| IGF-1 LR3 activates mTOR / protein synthesis | In vitro and rodent studies; mechanistic extrapolation in humans | Positive in cell and animal models | Moderate (mechanism), Low (human outcome) |
| Ipamorelin selectivity for GHS-R1a vs cortisol | Rodent pharmacology; limited human PK data | Positive (less off-target than GHRP-6) | Moderate |
| GHRP-2 raises GH in humans | Multiple small human studies (e.g., Bowers et al.) | Positive | Moderate |
| BPC-157 aids tendon/muscle recovery | Rodent studies only | Positive in animals | Very Low (for humans) |
| CJC-1295 + ipamorelin stack produces synergistic GH pulse | Mechanistic rationale; no stack-specific human RCT | Mechanistically plausible | Very Low |
Mechanism with Numbers: How These Peptides Build Muscle
All meaningful bulking peptides funnel through two interconnected pathways: the somatotropic axis and the IGF-1 receptor cascade.
GHRH analogs (CJC-1295): Bind GHRH receptors on somatotrophs in the anterior pituitary, increasing cyclic AMP and triggering GH secretion. CJC-1295 with DAC has a molecular weight of approximately 3367 Da and the Drug Affinity Complex binds albumin non-covalently, extending plasma half-life to roughly 6 to 8 days vs under 7 minutes for native GHRH. In the Teichman et al. 2006 trial, a single injection of 1 to 2 mcg/kg produced a 2 to 10 fold increase in mean GH concentration over 6 days and IGF-1 levels remained elevated for up to 28 days at higher doses. What this does NOT prove: elevated IGF-1 levels do not automatically translate to proportional muscle hypertrophy in otherwise healthy, well-nourished adults.
GHRPs (ipamorelin, GHRP-2): Bind the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, acting synergistically with GHRH. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) with roughly 30-minute half-life. It has higher selectivity for GHS-R1a than GHRP-2, meaning less concurrent ACTH/cortisol and prolactin release, which matters in a bulking context because chronic cortisol elevation is catabolic.
IGF-1 LR3: A 83 amino acid analog with a 13 amino acid N-terminal extension and an Arg to Glu substitution at position 3, reducing binding to IGF-binding proteins. Estimated half-life is 20 to 30 hours vs roughly 15 minutes for native IGF-1. Signals through IGF-1R, activating the PI3K/Akt/mTOR complex 1 pathway, which phosphorylates S6K1 and 4E-BP1 to increase ribosomal protein synthesis. It also activates the Ras/MAPK pathway, promoting satellite cell proliferation. The honest caveat: most quantitative data on IGF-1 LR3 binding and downstream signaling come from in vitro muscle cell studies or rodent models. Dose-response data in healthy human skeletal muscle are not established in published literature.
The Ranked List: 5 Best Peptides for Bulking
1. IGF-1 LR3 (Strongest Direct Anabolic Signal)
IGF-1 LR3 acts downstream of GH, directly at the muscle cell. Its extended half-life and reduced IGFBP binding make it the most potent standalone anabolic peptide on this list by mechanism. Research doses typically range from 20 to 100 mcg per day in rodent-to-human extrapolations, but hypoglycemia is a real risk and there are no published phase II human trials for muscle hypertrophy in healthy adults. Risk-to-benefit calculation is unfavorable at higher doses.
2. CJC-1295 with DAC (Best Human Evidence Base)
The only peptide on this list with a peer-reviewed phase II human trial. Documented increases in GH and IGF-1 in healthy adults. Weekly or twice-monthly dosing is practical. The trade-off is blunted pulsatility: constant GH elevation from albumin-bound CJC-1295 may reduce pituitary sensitivity over time compared to pulsatile secretagogue use.
3. Ipamorelin (Best Safety Profile Among GHRPs)
Highly selective GHRP with minimal cortisol and prolactin co-secretion. Best used in combination with a GHRH analog. Its short half-life (roughly 30 minutes) means timing relative to sleep (when endogenous GH pulsatility peaks) matters operationally. It does not cause the hunger surge that GHRP-6 does, which is relevant for athletes managing caloric surplus deliberately.
4. GHRP-2 (Potent but Less Selective)
Produces larger GH pulses than ipamorelin in some comparisons but co-secretes more cortisol and prolactin via non-GHS-R1a activity. Multiple small human studies confirm GH-stimulating activity. More appropriate for short-term diagnostic or pulse protocols than sustained bulking cycles due to off-target hormonal effects.
5. BPC-157 (Recovery Adjunct Only)
Does not meaningfully raise GH or IGF-1. Its proposed role in bulking is reducing downtime from connective tissue injuries, allowing more consistent training volume. All evidence comes from rodent studies. Zero published human RCTs. Include it with realistic expectations and recognize it is ranked fifth precisely because the evidence does not support a direct anabolic claim.
What Most Pages Get Wrong About Bulking Peptides
Underdosing is epidemic in the research peptide market. Independent analyses of commercial "research peptide" vials have repeatedly found actual peptide content substantially below label claims. Without a mass-spec COA you have no reliable way to know the true dose you are administering. This matters because dose-response curves for GH secretagogues are non-linear: too little produces no effect, too much can desensitize receptors.
The tumor promotion question is systematically avoided. IGF-1 signaling is one of the most studied pro-growth pathways in oncology. Chronically elevated IGF-1 is epidemiologically associated with increased risk of colorectal, prostate, and breast cancers in observational data. This does not prove that short-term exogenous IGF-1 LR3 use causes cancer in healthy people, but any honest discussion of IGF-1 analogs must acknowledge this signaling overlap rather than pretend it does not exist.
Pulsatility matters and most stacks ignore it. GH's anabolic and lipolytic effects depend in part on pulsatile secretion patterns. CJC-1295 with DAC produces a constant "GH bleed" that suppresses normal pulsatility. Some endocrinologists argue this is a worse long-term pattern than the natural pulse architecture, even if mean GH area-under-curve is higher.
The Chemistry Behind Storage and Stability Rules
Why lyophilized peptides survive but reconstituted ones do not: In lyophilized (freeze-dried) form, peptides lack the water molecules needed for hydrolysis of the peptide bond. Removing water halts most degradation pathways. Once you reconstitute in bacteriostatic water, hydrolysis can proceed, and the rate roughly doubles for every 10 degree Celsius rise in temperature (Arrhenius relationship). This is why reconstituted peptides stored at room temperature degrade measurably within days rather than weeks.
Why light matters: Tryptophan, tyrosine, and phenylalanine residues (all present in GHRPs) are photosensitive. UV exposure generates reactive oxygen species that oxidize methionine residues and cause disulfide scrambling. Store amber vials or foil-wrapped vials at 2 to 8 degrees Celsius, away from light.
Why bacteriostatic water rather than sterile water: Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial growth and allows multi-dose use over the 2 to 4 week window. Sterile water has no preservative; once opened, it is single-use only. The benzyl alcohol concentration in bacteriostatic water is low enough to be safe for subcutaneous injection but is contraindicated in neonates.
What a degraded peptide looks like: Cloudiness or visible particulate in a reconstituted peptide that should be clear is a red flag for aggregation or contamination. A significant color shift (yellowing) suggests oxidation. Degraded product may still test as "peptide present" on an HPLC but show multiple impurity peaks instead of a single clean peak at the correct retention time.
Honest Head-to-Head: Peptides vs Real Alternatives
| Compound | Anabolic Effect Size (Human Data) | Androgenic Risk | Approved for Muscle Gain | WADA Banned | Where Peptides Lose |
|---|---|---|---|---|---|
| CJC-1295 + Ipamorelin | Small to moderate (indirect, via GH/IGF-1) | Very low | No | Yes (S2) | Effect size, cost, injection frequency |
| IGF-1 LR3 | Unknown in humans (strong animal data) | Very low | No (mecasermin only for pediatric GHD) | Yes (S2) | No human efficacy RCT for hypertrophy; hypoglycemia risk |
| Testosterone (TRT doses) | Large (multiple RCTs, e.g., Bhasin et al.) | Moderate to high | Yes (for hypogonadism) | Yes (S1) | Peptides lose on raw lean mass gain per unit time |
| Recombinant GH (somatropin) | Moderate (increases lean mass, reduces fat; not pure anabolic in healthy adults) | Very low | Yes (for GHD, not healthy adults) | Yes (S2) | Peptides lose on direct GH equivalence; somatropin is the reference standard |
| Creatine monohydrate | Small to moderate (robust RCT base, ISSN endorsed) | None | Not a drug; OTC supplement | No | Peptides lose on evidence quality, safety profile, and legality |
Dosing and Protocol Table
| Peptide | Published Research Dose Range | Frequency | Route | Typical Cycle Length (Reported) | Key Caution |
|---|---|---|---|---|---|
| CJC-1295 with DAC | 1 to 2 mcg/kg (Teichman et al.) | Once weekly to biweekly | Subcutaneous | 8 to 16 weeks | Pulsatility suppression; water retention |
| Ipamorelin | 200 to 300 mcg per injection (research context) | 1 to 3x daily, pre-sleep preferred | Subcutaneous | 8 to 12 weeks | Receptor desensitization with chronic use |
| GHRP-2 | 100 to 300 mcg per injection (small human studies) | 2 to 3x daily | Subcutaneous | 6 to 12 weeks | Cortisol and prolactin co-release; hunger stimulus |
| IGF-1 LR3 | 20 to 100 mcg/day (extrapolated; no approved human bulking dose) | Once daily | Subcutaneous or IM | 4 to 6 weeks (anecdotal; longer raises concern) | Hypoglycemia; no human safety data at these doses |
| BPC-157 | 1 to 10 mcg/kg (rodent studies; no approved human dose) | Once to twice daily | Subcutaneous or oral | Variable (4 to 8 weeks anecdotally) | No human RCT data; FDA has flagged concerns about unapproved use |
Label and COA Literacy: How to Evaluate a Product
What a real COA must contain:
- Peptide identity confirmed by mass spectrometry (the molecular ion should match the theoretical MW within 1 Da for small peptides)
- Purity by HPLC shown as a chromatogram, not just a percentage number (you want to see a single dominant peak)
- Lot or batch number that matches the vial label
- Endotoxin (LAL) test result below 1 EU/mg for injectable use
- Issuing lab name and date (COAs over 12 months old are suspect for the specific lot)
Reconstitution math example (CJC-1295 with DAC, 2 mg vial, target dose 1 mg per injection): Add 2 mL bacteriostatic water to the vial. Each 1 mL drawn = 1 mg of peptide. Use a 1 mL insulin syringe. If target dose is 500 mcg (0.5 mg): draw 0.5 mL. Label the vial with the date of reconstitution and discard after 28 days at 4 degrees Celsius regardless of remaining volume.
Red flags on vendor pages: No third-party COA link, COA only shows a purity percentage with no chromatogram, no endotoxin testing listed, molecular weight listed in a range rather than a specific figure, and claims of "pharmaceutical grade" without any regulatory certification to back it.
FAQ
What are the best peptides for bulking?
The peptides with the strongest evidence for lean mass gain are IGF-1 LR3, CJC-1295 with DAC, ipamorelin, BPC-157 (as a recovery adjunct), and GHRP-2. Each works through a different mechanism and the evidence base ranges from human clinical data to animal studies only.
Do peptides actually build muscle?
Some do, under specific conditions. Growth hormone secretagogues raise IGF-1 and GH pulse amplitude, which stimulates protein synthesis. Human trials with CJC-1295 showed increased GH and IGF-1 levels, but direct lean mass gain in healthy adults has not been proven in large RCTs. The anabolic effect is real but modest compared to approved anabolics.
Is IGF-1 LR3 the strongest peptide for muscle growth?
IGF-1 LR3 has the most direct anabolic mechanism, binding IGF-1R to activate PI3K/Akt/mTOR. Its longer half-life (roughly 20 to 30 hours vs 15 minutes for native IGF-1) sustains receptor activation. However, human bulking data are very limited, and hypoglycemia risk is real at higher doses.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC binds albumin, extending half-life to roughly 6 to 8 days, allowing once-weekly dosing. Without DAC (also called Mod GRF 1-29), half-life is about 30 minutes, requiring multiple daily injections timed to mimic natural GH pulses. The DAC version blunts pulsatile GH release.
How long does it take for bulking peptides to work?
GH secretagogue peptides typically require 8 to 12 weeks before meaningful changes in body composition are noticeable. IGF-1 levels rise within the first two weeks. Visible lean mass changes in consistent users are generally reported after 10 to 16 weeks in anecdotal and open-label contexts.
Are bulking peptides safer than anabolic steroids?
In terms of androgenic side effects (prostate, hair loss, virilization), yes, peptides generally have a better profile. However, they carry their own risks: fluid retention, insulin resistance, potential tumor promotion via IGF-1 signaling, and injection-site reactions. Neither category is without risk.
Can you stack peptides for bulking?
Stacking a GHRH analog (CJC-1295) with a GHRP (ipamorelin or GHRP-2) is common because they act on different receptors and produce a synergistic GH pulse. The combination is mechanistically rational but human RCT data on the stack specifically are absent. Add-on risk accumulates with each compound.
What purity should I look for in research peptides?
A minimum of 98% purity by HPLC is the standard for research-grade peptides. A certificate of analysis (COA) should confirm purity, molecular weight by mass spectrometry, and endotoxin levels below 1 EU/mg for injectable use. Many vendors sell underdosed or degraded product; always request a third-party COA.
Do I need a prescription for bulking peptides?
In the United States, peptides like CJC-1295 and ipamorelin are not FDA-approved drugs and are not legally available as prescription compounds for healthy adults seeking muscle gain. They exist in a legal gray area as research chemicals. IGF-1 (mecasermin) is FDA-approved only for growth failure in children with IGF-1 deficiency.
How should bulking peptides be stored?
Lyophilized peptides should be stored at 2 to 8 degrees Celsius before reconstitution and protected from light. Once reconstituted in bacteriostatic water, most peptides are stable for roughly 2 to 4 weeks at 4 degrees Celsius. Repeated freeze-thaw cycles degrade the peptide bond and reduce potency.
What does BPC-157 do for bulking?
BPC-157 does not directly stimulate GH or IGF-1 in a meaningful way. Its proposed value in a bulking context is injury recovery and tendon-to-bone healing, allowing more consistent training. Evidence comes almost entirely from rodent studies; no human RCTs for muscle gain or injury recovery have been published.
Are bulking peptides banned in sport?
Yes. WADA prohibits GH-releasing peptides and factors (including GHRP-2, GHRP-6, CJC-1295, and ipamorelin) under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). IGF-1 and its analogs are also prohibited. Use in competitive sport carries serious anti-doping consequences.
Sources
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683.
- Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-1329.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822.
- Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335(1):1-7. PMID 8637535.
- Laron Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol Pathol. 2001;54(5):311-316. PMC1187088.
- Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279(5350):563-566. PMID 9438850.
- Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. PMC5333583.
- World Anti-Doping Agency. Prohibited List 2024: S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA, 2024. Available at wada-ama.org.
- FDA. Mecasermin (Increlex) prescribing information. Ipsen Biopharmaceuticals. Available at accessdata.fda.gov.
- Jørgensen JO, Rubeck KZ, Nielsen TS, et al. Effects of GH in human muscle and fat in vivo studied by proteomics and molecular physiology. Best Pract Res Clin Endocrinol Metab. 2008;22(1):27-37. PMID 18279776.
- FDA. FDA In Brief: FDA alerts consumers, health care professionals and compounders about risks associated with use of BPC-157. FDA News Release, 2023. Available at fda.gov.